Skip to Content
Merck
CN
  • Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Antimicrobial agents and chemotherapy (2009-03-05)
Ken B Waites, D M Crabb, Lynn B Duffy
ABSTRACT

MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)